Velsipity™
Drug class
- Non-biologic small molecule
- Non-biologic small molecule - S1P receptor modulator
Generic name
Etrasimod
Safety
Efficacy
Convenience
Indications
Approved for treatment of moderate to severe ulcerative colitis.
How it works
Targets and lessens the movement of white blood cells that cause inflammation.
Drug interactions
Anti-arrhythmic drugs and QT prolonging drugs, beta-blockers or calcium channel blockers, anti-neoplastic, immune-modulating, or non-corticosteroid immunosuppressive therapies, moderate to strong inhibitors of CYP2C9 and CYP3A4, CYP2C9 poor metabolizers using moderate to strong inhibitors of CYP2C8 or CYP3A4, and rifampin.
Pre-treatment screening tests
Complete blood count, including lymphocyte counts, bilirubin and transaminase levels in all patients prior to therapy initiation, electrocardiogram (ECG), ophthalmologic exam, blood pressure
Tests during screening
Complete blood count, including lymphocyte counts, bilirubin and transaminase levels, electrocardiogram (ECG), ophthalmologic exam and blood pressure. Report signs of infection, signs of liver dysfunction, signs of neuro dysfunction (behavioral changes, change in vision, weakness), or respiratory status changes.
Payment options
https://www.velsipity.com/savings-and-supportRoute of administration
Frequency
1 time every day
Side effects
Headache, high liver enzymes, and dizziness.
Contraindications
History of myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization or class III or IV heart failure in the last 6 months, history or presence of Mobitz type II second-degree or third-degree atrioventricular block, sick sinus syndrome, or sino-atrial block unless the patient has a functioning pacemaker.
Safety information
Unexplained nausea or upset stomach, vomiting, not feeling hungry, unexplained tiredness, dark urine, blurriness or sensitivity to light, sudden severe headache, sudden confusion, seizure, and breathing problems.